Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s New Leadership May Be More Amenable To Expanded Access Programs

This article was originally published in The Pink Sheet Daily

Executive Summary

Patient activists say shift in Iplex case shows that the agency may begin to allow more compassionate use for products in development.
Advertisement

Related Content

Hamburg, Sharfstein Appointments To FDA Shift Focus To Future Plans Of Career Officials
Hamburg, Sharfstein Appointments To FDA Shift Focus To Future Plans Of Career Officials
FDA’s Compassionate Use Policy: Is Tysabri A Precedent Or A Special Case?
Expanded Access Program For Insmed’s Iplex Shows Power Of Patient Advocates At FDA
Expanded Access Program For Insmed’s Iplex Shows Power Of Patient Advocates At FDA
FDA Widens Expanded Access, Will Accelerated Approval Gray Area Narrow?

Topics

Advertisement
UsernamePublicRestriction

Register

PS069129

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel